We open different perspectives to healthcare market players
Advising, projects & support for public and private health organizations Company profile - 2015
www.hittinnova.com
What’s the real meaning of ‘success’?
• 22 of these 23 people
have something in
common: they didn’t
set up a company.
Although no one
denies that they were
great scientists…
• Only one of them,
Ernst Solvay,
estabished a
succesful business.
Health Innovation Technology Transfer 1
Seated (L-R): Walther Nernst, Marcel Brillouin, Ernest Solvay, Hendrik Lorentz, Emil Warburg, Jean Baptiste Perrin, Wilhelm Wien, Marie Curie, and Henri Poincaré. Standing (L-R): Robert Goldschmidt, Max Planck, Heinrich Rubens, Arnold Sommerfeld, Frederick Lindemann, Maurice de Broglie, Martin Knudsen, Friedrich Hasenöhrl, Georges Hostelet, Edouard Herzen, James Hopwood Jeans, Ernest Rutherford, Heike Kamerlingh Onnes, Albert Einstein, and Paul Langevin.
www.hittinnova.com
Failure in BioTech is a constant
• If failure means liquidating all assets, with
investors losing most or all the money they
put into the company, then the failure rate for
start-ups is 30 to 40 percent
• If failure refers to failing to see the projected
return on investment, then the failure rate is
70 to 80 percent
• If failure is defined as declaring a projection
and then falling short of meeting it, then the
failure rate is a whopping 90 to 95 percent
Health Innovation Technology Transfer 2
Illusions of Entrepreneurship: The Costly Myths that Entrepreneurs, Investors, and Policy Makers Live Scott Shane , Professor of Entrepreneurial Studies at Case Western Reserve University
New business founded in 1992 still alive by year
www.hittinnova.com
Successful ways always jump outside the box
• Nowadays, independent and honest visions
are critical factors for success in the
innovation & technological projects of health
players.
• Through a different and unconventional
view, hitt generates relevant and timely
information for both public entities and
private companies, to inform their
investment and strategic development
decisions.
• Excellence, accountability and team efficiency
are our key performance advantages.
Health Innovation Technology Transfer 3
Technology life-cycle
www.hittinnova.com
Services
Health Innovation Technology Transfer 4
ADVISING Trusted independent advisors for public and private health
organizations
PROJECTS Experts consultants on
business, investment and clinical development strategies
SUPPORT High quality and broad reviews
of best state-of-the-art in health market
We deploy a full range of solutions to cover the main needs of knowledge of all
actors in health market.
www.hittinnova.com
The three pillars of development
Health Innovation Technology Transfer 5
Science Organization
Finance
Start-ups often fail because founders and investors neglect to
look before they leap, surging forward with plans without taking the time to realize that the base
assumption of the business plan is wrong. They believe they can
predict the future, rather than try to create a future with their
customers. Entrepreneurs tend to be single-minded with their
strategies—wanting the venture to be all about the technology or all about the sales, without taking
time to form a balanced plan. And all too often, they do not give themselves wiggle room to pivot
midstream if the initial idea doesn't jibe with customer
demand. Shikhar Ghosh, Senior Lecturer of Business Administration, Harvard
Business School
Registry Price Financing
Regulatory Health Authorities
FDA: security & efficacy
EMA: quality, safety & efficacy
CMS: Reasonable & Necessary
CatSalut: appropriate adjustment of supply to the health
needs of citizens NHS UK:
comprehensive range of services
Insurer
www.hittinnova.com
The current strategy…
Health Innovation Technology Transfer 6
Idea PoC Regulatory Clinical Development
Marketing / KOL
Commercial
Basic Science / Experts
Operations
www.hittinnova.com
… and the hitt approach
Health Innovation Technology Transfer 7
Marketing / KOL
Commercial
Basic Science / Experts
Operations
Primary
Research
Early
Stage
Market
Access Market
System Overview / Designing access strategies
www.hittinnova.com
Focus on
We design easier and more profitable ways for:
• To build and consolidate strategic decisions in market access for health products & services
• To support start-ups on their business strategy &development
• To generate primary research in health services
Health Innovation Technology Transfer 8
Primary
Research
Early
Stage
Market
Access Market
www.hittinnova.com
Providing key data
• Review of literature
• Develop a business strategy & implement business ‘thinking’
• Landscape analysis & define relevant outcomes
• Feasibility studies (cost / operational / clinical)
• Cost-Effectiveness & Budget impact analysis (Economic
Evaluation)
• Impacts on the organizations & on clinical management
• Analyse alternatives / comparators
• Propose pricing scenarios
Health Innovation Technology Transfer 9
Primary
Research
www.hittinnova.com
Early
Stage
Opening new paths to success
• design and implement roadmap
• validate research proposals
• validate expected outcomes
• assess business value
• refine value proposition
• early stage investing strategy
• design and implement clinical trials
Health Innovation Technology Transfer 10
www.hittinnova.com
Market
Access
Designing business strategies
• Analyse & propose possible pricing scenarios & strategies
• Recommend (and elaborate) value dossier content, and
incorporate HTA perspective
• Probe intangible value
• Economic evaluation of research findings
• Validate expectations of Return on Investment: inform on potential
risks and mitigate and arise threats
• Development phase projects:
• Definition of most relevant outcomes
• Research & economic evaluation trials
• Facilitate appropriate development of PoC and Research Trials: Sites, KOL.
Health Innovation Technology Transfer 11
www.hittinnova.com
Projects
• hitt develops projects for top pharma companies, start-ups, government agencies
and consultancy firms in health industry.
• Some of our clients are:
Alcon · Novartis · Biomarin · BiogenIdec · ALKAbelló · Bayer · Shire ·
Astellas · Otsuka · Astra Zeneca · Hartmann · Reig Jofre · Oryzon Genomics ·
Oliver Wymann · Quintiles · Ernst&Young · Deloitte · Ernest&Young ·
Simon Kutcher & Partners · Antares Consulting · UBC ·
IMS · Ysios Capital · Proa Capital
Health Innovation Technology Transfer 12
www.hittinnova.com
How we work?
• Independent and small dynamic team, knowledgeable of both the EU and US
environments
• Alliances with the best-of-breed providers.
• Incorporating ad-hoc specialists to achieve best available expertise on a
timely and high quality manner
• Based on a network of free-standing senior international collaborators, who
have been or are in strategic decision positions mainly in the EU.
• Two stage approach
• We shall inform our clients in less than 2 weeks on the foreseen outcome of
the project, allowing them to reshape objectives
Health Innovation Technology Transfer 13
www.hittinnova.com
c/Avenir, 1
08006 Barcelona
T. +34 650 161 197
Top Related